Dr. David Perlmutter
speaker
585 appearances
1 recordings
1 series
first heard Jul 2026
last heard 15 Jul
Dr. David Perlmutter’s voice in public audio — every appearance, attributed to the second.
Trend
recordings per month · last 12 monthsRecordings per month over the last 12 months — 1 in all, peaking in Jul 2026 with 1.
Appearances
So these researchers that I alluded to in 2024, they studied these individuals, half got a GLP-1 drug, everyday injection, full-on dosage, not a microdose.
The other half did not.
And what happened to the two groups?
The group that did not receive the GLP-1 drug
as expected over the one-year period of time, declined in their functionality.
They got worse.
The group receiving the GLP-1 drug not only stabilized, but actually had a tiny bit of an improvement
in their functionality.
Wow.
So that's targeting the fire, not just the smoke.
That's targeting the disease, not just the symptoms.
It's breathtaking.
So when I see that, I can't turn my backs on GLP-1 drugs because
In this study, for example, more than 40% of the people on the treatment side who got the GLP-1 drug had significant gastrointestinal issues, nausea, vomiting, etc.
So, you know, we have to think about managing side effects, but we've got to keep an open mind because, you know, in Alzheimer's, that is, call it what it is, it's a fatal condition.
We all know a cancer survivor.
Do we know an Alzheimer's survivor?
I don't.
Well, except for a couple of individuals who have been treated by Dr. Dale Bredesen.
He's got some fascinating results.
Showing 461–480 of 585 · page 24 of 30
← Previous
Next →